Forian Inc. - FORA Forward P/S Multiple

Official company branding of Forian (FORA)

Forian Inc. generates revenue by selling anonymized medical data to the US pharmaceutical industry. The expected P/S ratio demonstrates a long-term capitalization vector, with the metric standing at 2.30. Stable management is effectively reducing costs to drive profitability, while a team of high-paid compliance experts ensures the high-quality processing of data sets to improve healthcare.

FORA (forian.com) Market Cap to Expected Sales Ratio history from 07/04/2022 to 05/30/2026

FORA (Forian Corporation): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Forian|FORA - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Forian Corporation|FORA - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value per Share Forian|FORA - Book Valuation of Business|Market Capitalization to Book Value Ratio forian.com|FORA - Total Asset Value of Company
- debt level and financial liquidity data:
Debt to Equity Forian Inc.|FORA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Forian Inc.|FORA - Aggregate Debt Obligations|Debts to Book Capitalization Forian Corporation|FORA - Company Long-Term Debts|Company Short-Term Debts Forian|Quick Ratio forian.com
- net income and valuation multiples indicators:
FORA - Net Profit|Future Profit Forian Inc.|FORA - Market Price to Net Income Ratio|Forward P/E Multiple Forian Inc|FORA - PEG Multiple|EV/EBITDA Multiple Forian Corporation|FORA - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Forian|FORA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months forian.com|FORA - Earnings per share increase in current year|Earnings growth forecast for next year Forian Inc.
- sales volume and revenue indicators:
FORA - Company Gross Revenue|Projected Sales Volume Forian|FORA - P/S Multiple|Price-to-Projected Revenue Ratio Forian Corporation
Summary company analysis:Forian FORA
Original product of Forian Inc.

For Forian Inc. (FORA), with its deep integration into the R&D processes of pharmaceutical behemoths, this indicator reflects a market premium for the high stability of future subscription flows. By analyzing the expected price-to-sales ratio, an investor assesses the value of every dollar of projected revenue, which allows for the timely identification of speculative imbalances or the onset of a long-term fundamental revaluation of the business.

Competitors of Forian Inc.

Price-to-Projected Revenue Ratio RELX Group RELX|CSGP: Market Cap to Projected Revenue|Verisk Analytics Inc - Forward P/S Multiple|Equifax Credit (EFX) - Forward Price-to-Revenue Multiple|IT (Gartner, Inc.) - Forward Price-to-Revenue Multiple|TRU - Market Cap to Expected Sales Ratio|FDS (FactSet) - Forward P/S Multiple|Morningstar Inc - Future Price to Revenue|Price-to-Projected Revenue Ratio ZoomInfo Inc (GTM)|PL - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Clarivate Plc CLVT|Forward Price to Sales INOD|Similarweb - Forward P/S Multiple|PDFS - Forward P/S Multiple|TTGT: Forward P/S Multiple|Market Cap to Projected Revenue FORR|NOTE (FiscalNote Holdings) - Forward P/S Multiple|Forward P/S Multiple dnb.com|Forward Price-to-Revenue Multiple MTTR (Matterport)|Price to Expected Revenue Ratio ZI